Brief: Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial
17/08/2026 01:49
BRIEF-Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial Aug 17 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
SAYS ORPATHYS PLUS TAGRISSO IMPROVES SURVIVAL IN EGFR-MUTATED NSCLC IN PHASE III TRIAL
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation